<DOC>
	<DOCNO>NCT02740335</DOCNO>
	<brief_summary>To demonstrate efficacy OCTAPLEX reversal agent patient Vitamin K Antagonist ( VKA ) therapy need urgent surgery significant bleeding risk clinically non-inferior Beriplex® P/N ( Kcentra ) .</brief_summary>
	<brief_title>Study Octaplex , Four-factor Prothrombin Complex Concentrate ( 4F-PCC ) Beriplex® P/N ( Kcentra ) Reversal Vitamin K Antagonist ( VKA ) Induced Anticoagulation Patients Needing Urgent Surgery With Significant Bleeding Risk .</brief_title>
	<detailed_description>The primary objective study demonstrate efficacy OCTAPLEX reversal agent patient Vitami n K Antagonist ( VKA ) therapy need urgent surgery significant bleeding risk clinically non-inferior Beriplex® P/N ( Kcentra ) . The secondary objective study investigate safety tolerability OCTAPLEX compare Beriplex® P/N ( Kcentra ) patient Vitamin K Antagonist ( VKA ) therapy need urgent surgery significant bleeding risk .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Protein S</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female patient least 18 year age . 2 . Patients currently oral anticoagulation treatment VKA coumadin warfarin type . 3 . Patients admitted hospital currently hospitalize : urgent surgery carry significant bleeding risk ( ≥50 mL expect blood loss ) require part routine clinical care ; use oral parenteral vitamin K alone reverse anticoagulation deem slow inappropriate reversal ; 4 . Patients international normalize ratio ( INR ) 2.0 time decision reverse anticoagulation status . 5 . Patients give write informed consent able willing comply procedure describe study protocol . Exclusion Criteria 1 . Patients life expectancy le 48 hour per physician 's judgment ( e.g . patient Glasgow Coma Scale equal 3 Head Abbreviated Injury Score 6 , patient require continuous inotropic pressor support , patient whose status post cardiac arrest ) . 2 . Patients plan surgery procedure commonly associate low bleeding risk ( e.g . catheter placement , gastroscopy ) . 3 . Patients history thromboembolic event ( TEEs ) , myocardial infarction , unstable angina pectoris , critical aortic stenosis , cerebrovascular accident , transient ischemic attack , severe peripheral vascular disease , disseminate intravascular coagulation within 3 month enrollment . 4 . Patients know congenital bleeding disorder . 5 . Patients know antiphospholipid antibody syndrome . 6 . Patients present past specific factor inhibitor activity . 7 . Patients thrombocytopenia &lt; 80,000/μL history heparininduced thrombocytopenia . 8 . Patients receive heparin type nonVKA anticoagulant within 24 hour prior enrollment study potential need receive medication completion hemostasis evaluation end surgery . 9 . Patients receive prothrombin complex concentrate ( PCCs ) , fresh frozen plasma vitamin K within 72 hour prior enrollment study . 10 . Patients known history hypersensitivity plasmaderived product . 11 . Patients acute major bleed polytrauma . 12 . Pregnant nursing woman . 13 . Patients participate another interventional clinical study currently past 30 day prior enrollment study . 14 . Patients previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>anticoagulant reversal</keyword>
	<keyword>urgent surgery</keyword>
	<keyword>invasive procedure</keyword>
	<keyword>vitamin K</keyword>
	<keyword>prothrombin complex concentrate</keyword>
	<keyword>four-factor prothrombin complex concentrate ( 4F-PCC )</keyword>
</DOC>